BioGaia, Nestle infant formula
This article was originally published in The Tan Sheet
Executive SummaryBioGaia will provide Lactobacillus reuteri probiotic to Nestle Nutrition for use in infant formula products, the Stockholm, Sweden-based biotechnology firm says Aug. 21. BioGaia President Peter Rothschild credits the firm's probiotic safety data as "a strong factor in facilitating the agreement with Nestle," which has an existing partnership with BioGaia in the health care nutrition area. The infant formula deal will cover all world markets, excluding Korea and Japan, with an initial product launch planned for 2009
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.